Xenter, Inc.
- Industry
- Medical Devices
- Founded Year
- 2020
- Headquarters
- 344 West 13800 South, Suite 400, Draper, UT 84020
- Employee Count
- 50
Key People
- Richard J. Linder - Founder, Chief Executive Officer & Chairman
- David J. Bearss - President, Xenter Therapeutics
- Scott Heuler - Senior Vice President of Global Sales & Marketing
- Gary Baldwin - Chief Technology Officer
- Robert Baxter - Chief Business Officer & Board Member
- Scott Texley - Chief Quality Officer
- Bret Peterson - Vice President of Finance
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in medical device development and commercialization.
Richard J. Linder, the founder and CEO, has a history of leading successful medical device companies, including Coherex Medical and CoNextions Medical. Other key executives, such as Gary Baldwin and Scott Heuler, bring significant expertise in technology development and sales within the medical device industry.
- Clinical Need
-
Aspect: Very Strong
Summary: Xenter addresses a critical need for wireless medical devices that provide real-time physiological data, enhancing patient outcomes.
Current interventional procedures often lack real-time physiological data, leading to suboptimal outcomes. Xenter's wireless devices aim to fill this gap by providing continuous, accurate data during procedures, thereby improving decision-making and patient care.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for interventional cardiology devices is competitive, with several established players.
Major companies like Medtronic and Boston Scientific dominate the interventional cardiology space. However, Xenter's focus on wireless, data-driven devices provides a novel approach that could carve out a niche in this crowded market.
- Technical Challenge
-
Aspect: Complex
Summary: Developing wireless medical devices that integrate seamlessly with existing systems presents significant technical challenges.
Ensuring reliable wireless communication within the human body, maintaining device sterility, and achieving regulatory approval are complex tasks that require substantial R&D investment and expertise.
- Patent
-
Aspect: Strong
Summary: Xenter has a robust patent portfolio covering its wireless medical device technologies.
The company's patents encompass various aspects of its wireless medical devices, including sensor integration and data transmission methods, which are critical to its technology platform.
- Financing
-
Aspect: Well-funded
Summary: Xenter has secured significant funding, including a $12 million Series A round and subsequent debt financing.
The Series A funding, led by Sagamore BioVentures, along with additional debt financing, provides the necessary capital for R&D, regulatory processes, and initial commercialization activities.
- Regulatory
-
Aspect: Running FIH
Summary: Xenter is in the early stages of regulatory approval, with first-in-human trials underway.
Initiating first-in-human trials indicates that the company has developed a prototype ready for clinical evaluation, marking a critical milestone in the regulatory pathway.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 4.7
- Segment CAGR
- 4.0%
- Market Segment
- Interventional Cardiology Devices
- Market Sub Segment
- Wireless Guidewires and Catheters
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.71 |
| 3 | 1.65 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
Xenter's innovative wireless medical devices address a significant clinical need, supported by a strong team and patent portfolio, positioning the company for potential success in a competitive market.